A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

NCT04755244 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2.

Conditions

Interventions

Sponsor

ALX Oncology Inc.